目的 探討鹽酸氨溴索霧化治療新生兒肺炎的臨床療效及對(duì)患兒炎癥因子的影響。方法 選取2016年1月-2018年5月于蚌埠市第一人民醫(yī)院住院治療的新生兒肺炎患兒100例，采用隨機(jī)數(shù)字法分為對(duì)照組和觀察組，每組50例，對(duì)照組給予常規(guī)治療，觀察組在常規(guī)治療基礎(chǔ)上給予鹽酸氨溴索霧化吸入。治療7 d后比較兩組患者的臨床治療有效率、肺部啰音消失時(shí)間、呼吸困難消失時(shí)間及咳嗽消失時(shí)間，并采用酶聯(lián)免疫吸附測(cè)定法測(cè)定血清白介素-6（IL-6）、C反應(yīng)蛋白（CRP）及腫瘤壞死因子-α（TNF-α）的水平。結(jié)果 觀察組患兒的臨床總有效率為94.00%，對(duì)照組患兒的臨床總有效率為76.00%，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。與對(duì)照組相比，觀察組患者的肺部啰音消失時(shí)間、呼吸困難消失時(shí)間及咳嗽消失時(shí)間均顯著縮短，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者的IL-6、CRP及TNF-α均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組患者的IL-6、CRP及TNF-α均顯著低于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組患兒不良反應(yīng)發(fā)生率為8.00%，對(duì)照組患兒不良反應(yīng)發(fā)生率為10.00%，差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 鹽酸氨溴索霧化治療可顯著改善新生兒肺炎的臨床癥狀，有效降低患兒的炎癥因子水平，治療效果較好。

Objective To investigate the clinical effect of ambroxol in the treatment of newborn pneumonia and its effect of inflammatory factor of child patient.Methods 100 cases newborn pneumonia patients were corrected from January 2016 May 2018 in First people's hospital of Bengbu, according to the random number method divided into control group and treatment group, with 50 cases in each group, the control group was given routine treatment, the treatment group was given ambroxol hydrochloride injection on the basis of routine treatment, compared with the effective clinical treatment, lung murmur goes out of time, breathing difficulties disappear time and cough disappearance time of the two groups, and tested the serum level of interleukin 6, C-reactive protein and tumornecrosis factor alpha by enzyme linked immunosorbent assay.Results The clinical total effective rate of the child patient with treatment group was 94.00%, the clinical total effective rate of the child patient with control group was 76.00%, the difference was statistically significant (P<0.05). Compared with the control group, the lung murmur goes out of time, breathing difficulties disappear time and cough disappearance time both significantly shortened, the difference was statistically significant (P<0.05). Before treatment, compared with the IL-6, CRP and TNF-α of the treatment and control group, the difference was not statistically significant. After treatment, the IL-6, CRP and TNF-α of the treatment group significantly lower than control group, the difference was statistically significant (P<0.05). The incidence of adverse reaction of the child patient with treatment group was four cases (8.00%), the incidence of adverse reaction of the child patient with control group was five cases (10.00%), the difference was not statistically significant.Conclusion Ambroxol can significantly improved the clinical symptoms of newbornpneumonia, and can effectively reduce the level of inflammatory factors in children and has good therapeutic effect.